Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 173

1.

Evaluation of phage display discovered peptides as ligands for prostate-specific membrane antigen (PSMA).

Shen D, Xie F, Edwards WB.

PLoS One. 2013 Jul 25;8(7):e68339. doi: 10.1371/journal.pone.0068339. Print 2013.

2.
3.

A dimeric peptide that binds selectively to prostate-specific membrane antigen and inhibits its enzymatic activity.

Aggarwal S, Singh P, Topaloglu O, Isaacs JT, Denmeade SR.

Cancer Res. 2006 Sep 15;66(18):9171-7.

4.

Screening of a specific peptide binding to VPAC1 receptor from a phage display peptide library.

Tang B, Li Z, Huang D, Zheng L, Li Q.

PLoS One. 2013;8(1):e54264. doi: 10.1371/journal.pone.0054264. Epub 2013 Jan 24.

5.

Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models.

Denmeade SR, Sokoll LJ, Dalrymple S, Rosen DM, Gady AM, Bruzek D, Ricklis RM, Isaacs JT.

Prostate. 2003 Mar 1;54(4):249-57.

PMID:
12539223
6.

Cloning and characterization of canine prostate-specific membrane antigen.

Schmidt S, Fracasso G, Colombatti M, Naim HY.

Prostate. 2013 May;73(6):642-50. doi: 10.1002/pros.22605. Epub 2013 Jan 28.

PMID:
23359458
7.

Development of novel peptide ligands modulating the enzyme activity of prostate-specific antigen.

Leinonen J, Wu P, Koivunen E, Närvänen A, Stenman UH.

Scand J Clin Lab Invest Suppl. 2000;233:59-64.

PMID:
11317943
8.

Metastatic prostate cancer cell-specific phage-like particles as a targeted gene-delivery system.

Fagbohun OA, Kazmierczak RA, Petrenko VA, Eisenstark A.

J Nanobiotechnology. 2013 Sep 23;11:31. doi: 10.1186/1477-3155-11-31.

9.

Prostate-specific antigen, its molecular forms, and other kallikrein markers for detection of prostate cancer.

Stephan C, Jung K, Diamandis EP, Rittenhouse HG, Lein M, Loening SA.

Urology. 2002 Jan;59(1):2-8. Review. No abstract available.

PMID:
11796270
10.

Binding of prostate-specific membrane antigen to dendritic cells: a critical step in vaccine preparation.

Garetto S, Sizzano F, Brusa D, Tizzani A, Malavasi F, Matera L.

Cytotherapy. 2009;11(8):1090-100. doi: 10.3109/14653240903164971.

PMID:
19929472
11.

Prostate-specific membrane antigen and its truncated form PSM'.

Mlcochová P, Barinka C, Tykvart J, Sácha P, Konvalinka J.

Prostate. 2009 Apr 1;69(5):471-9. doi: 10.1002/pros.20894.

PMID:
19107881
12.

Screening and identification of a novel hepatocellular carcinoma cell binding peptide by using a phage display library.

Zhu X, Wu H, Luo S, Xianyu Z, Zhu D.

J Huazhong Univ Sci Technolog Med Sci. 2008 Jun;28(3):299-303. doi: 10.1007/s11596-008-0316-1. Epub 2008 Jun 19.

PMID:
18563328
13.

Identification of novel prostate-specific antigen-binding peptides modulating its enzyme activity.

Wu P, Leinonen J, Koivunen E, Lankinen H, Stenman UH.

Eur J Biochem. 2000 Oct;267(20):6212-20.

14.

DNA fusion gene vaccines induce cytotoxic T-cell attack on naturally processed peptides of human prostate-specific membrane antigen.

Vittes GE, Harden EL, Ottensmeier CH, Rice J, Stevenson FK.

Eur J Immunol. 2011 Aug;41(8):2447-56. doi: 10.1002/eji.201141518. Epub 2011 Jul 4.

15.

PSMA mimotope isolated from phage displayed peptide library can induce PSMA specific immune response.

Zhu ZY, Zhong CP, Xu WF, Lin GM, Ye GQ, Ji YY, Sun B, Yeh M.

Cell Res. 1999 Dec;9(4):271-80.

16.

Further investigation of the epitope recognized by the new monoclonal antibody 2C9.

Kato K, Yoshikawa K, Taki T, Shitara K, Nakamura K, Hirota M, Hanai N, Nakamura K, Kokubo H, Mitsui K, Yamada Y, Honda N, Ueda R, Saga S, Fukatsu H.

Int J Urol. 2003 Aug;10(8):439-44.

17.

Adenovirus targeting to prostate-specific membrane antigen through virus-displayed, semirandom peptide library screening.

Wu P, Kudrolli TA, Chowdhury WH, Liu MM, Rodriguez R, Lupold SE.

Cancer Res. 2010 Dec 1;70(23):9549-53. doi: 10.1158/0008-5472.CAN-10-1760. Epub 2010 Jul 29.

18.

Anti-prostate-specific membrane antigen liposomes loaded with 225Ac for potential targeted antivascular α-particle therapy of cancer.

Bandekar A, Zhu C, Jindal R, Bruchertseifer F, Morgenstern A, Sofou S.

J Nucl Med. 2014 Jan;55(1):107-14. doi: 10.2967/jnumed.113.125476. Epub 2013 Dec 12.

19.

Screening a phage display library for a novel FGF8b-binding peptide with anti-tumor effect on prostate cancer.

Wang W, Chen X, Li T, Li Y, Wang R, He D, Luo W, Li X, Wu X.

Exp Cell Res. 2013 May 1;319(8):1156-64. doi: 10.1016/j.yexcr.2013.02.007. Epub 2013 Mar 4.

PMID:
23466786
20.

High expression of PSM-E correlated with tumor grade in prostate cancer: a new alternatively spliced variant of prostate-specific membrane antigen.

Cao KY, Mao XP, Wang DH, Xu L, Yuan GQ, Dai SQ, Zheng BJ, Qiu SP.

Prostate. 2007 Dec 1;67(16):1791-800.

PMID:
17929272
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk